30 nov 2017 año - FDA approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine- containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.
Añadido al timeline:
fecha:
30 nov 2017 año
Ahora mismo
~ 7 years and 10 months ago